| human | Q5 |
| P691 | NL CR AUT ID | xx0095208 |
| P496 | ORCID iD | 0000-0002-4288-5973 |
| P1153 | Scopus author ID | 7006815656 |
| P214 | VIAF ID | 86425788 |
| P4789 | Who's Who UK ID | U277809 |
| P512 | academic degree | Doctor of Medicine | Q913404 |
| P166 | award received | Fellow of the Academy of Medical Sciences | Q24081923 |
| Fellow of the Royal College of Physicians of London | Q26204035 | ||
| P69 | educated at | Academy of Medical Sciences | Q4671486 |
| P108 | employer | University of Oxford | Q34433 |
| University of Leicester | Q1333399 | ||
| Chelsea and Westminster Hospital | Q5090151 | ||
| Glenfield Hospital | Q5568506 | ||
| McMaster University Medical Centre | Q6802330 | ||
| Nottingham City Hospital | Q7063615 | ||
| Rochford Hospital | Q30292818 | ||
| P735 | given name | Ian | Q18336315 |
| Ian | Q18336315 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q57415821 | A case for serial examination of sputum inflammatory cells |
| Q35534773 | A case of cough, lymphocytic bronchoalveolitis and coeliac disease with improvement following a gluten free diet. |
| Q57415827 | A comparison of the effects of inhaled furosemide and ethacrynic acid on sodium-metabisulfite-induced bronchoconstriction in subjects with asthma |
| Q43955597 | A comparison of the validity of different diagnostic tests in adults with asthma. |
| Q50493732 | A cross-sectional study of patterns of airway dysfunction, symptoms and morbidity in primary care asthma. |
| Q39455262 | A longitudinal assessment of acute cough. |
| Q39294362 | A new approach to the classification and management of airways diseases: identification of treatable traits |
| Q37256164 | A new perspective on concepts of asthma severity and control. |
| Q51490048 | A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. |
| Q35677389 | A randomised controlled trial of small particle inhaled steroids in refractory eosinophilic asthma (SPIRA). |
| Q47568455 | A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial |
| Q41014491 | A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis |
| Q38487823 | A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma |
| Q50138360 | A retrospective cohort study in severe asthma describing commonly measured biomarkers: Eosinophil count and IgE levels. |
| Q35909905 | A systematic review of fractional exhaled nitric oxide in the routine management of childhood asthma |
| Q57415721 | A tale of two letters |
| Q48566249 | A worldwide survey of chronic cough: a manifestation of enhanced somatosensory response. |
| Q94473312 | Achieving the balance between evidence and simplicity |
| Q50518501 | Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. |
| Q35563428 | Adenosine monophosphate and histamine induced bronchoconstriction: repeatability and protection by terbutaline |
| Q47775191 | After the asthmas: Star Wars and Star Trek |
| Q57415741 | Airway Dysfunction and Inflammation in Pool- and Non–Pool-Based Elite Athletes |
| Q35746774 | Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function. |
| Q35537524 | Airway function and markers of airway inflammation in patients with treated hypothyroidism |
| Q37711408 | Airway hyperresponsiveness is dissociated from airway wall structural remodeling. |
| Q46050008 | Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol |
| Q53913323 | Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis. |
| Q57415784 | Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis |
| Q36080147 | Allergic rhinitis, asthma, airway biology, and chronic obstructive pulmonary disease in AJRCCM in 2004. |
| Q46522261 | Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. |
| Q51908105 | An automated system for 24-h monitoring of cough frequency: the leicester cough monitor. |
| Q37522916 | An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice |
| Q35534841 | Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids |
| Q57415776 | Antagonism of tumour necrosis factor in refractory asthma |
| Q52723583 | Anti-IgE for asthma in inner-city children. |
| Q46902397 | Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease |
| Q44484408 | Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease |
| Q51061575 | Aspergillus fumigatus during stable state and exacerbations of COPD. |
| Q38118606 | Assessing the risk of attack in the management of asthma: a review and proposal for revision of the current control-centred paradigm. |
| Q57415773 | Assessment of gender differences in health status with the Leicester Cough Questionnaire (LCQ) |
| Q57415812 | Association between - 308 tumour necrosis factor promoter polymorphism and bronchial hyperreactivity in asthma |
| Q50662075 | Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. |
| Q34840443 | Association between pathogens detected using quantitative polymerase chain reaction with airway inflammation in COPD at stable state and exacerbations. |
| Q52644132 | Associations between blood eosinophils and decline in lung function among adults with and without asthma. |
| Q57415739 | Asthma Phenotypes |
| Q39491549 | Asthma control during and after cessation of regular beta 2-agonist treatment |
| Q53199152 | Asthma control during the year after bronchial thermoplasty. |
| Q57415769 | Asthma control, airway responsiveness and airway inflammation |
| Q38371020 | Asthma diagnosis: addressing the challenges |
| Q44247874 | Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. |
| Q43702009 | Asthma guidelines |
| Q57415688 | Asthma-like Features and Chronic Obstructive Pulmonary Disease |
| Q47159531 | Author Correction: The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β2-agonists in the United Kingdom: a cross-sectional analysis |
| Q40131564 | Azithromycin in uncontrolled asthma |
| Q55094032 | Between-observer repeatability of sputum differential cell counts. Influence of cell viability and squamous cell contamination |
| Q34808077 | Biological clustering supports both "Dutch" and "British" hypotheses of asthma and chronic obstructive pulmonary disease. |
| Q51643473 | Biomarkers and inhaled corticosteroid responsiveness in asthmatic patients. |
| Q47314379 | Biomarkers for severe eosinophilic asthma |
| Q37388264 | Biomarkers in the assessment and management of airways diseases. |
| Q36246749 | Biomarkers predicting response to corticosteroid therapy in asthma. |
| Q40017988 | Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD. |
| Q47820367 | Blood eosinophil count and exacerbation risk in patients with COPD. |
| Q39558323 | Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis |
| Q40401116 | Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study |
| Q51529150 | Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease. |
| Q51603278 | Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD?--Authors' reply. |
| Q30933471 | Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials |
| Q51717201 | Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. |
| Q36577253 | Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD |
| Q38391330 | Blood eosinophils as a marker of likely corticosteroid response in children with preschool wheeze: time for an eosinophil guided clinical trial? |
| Q36105874 | Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial |
| Q34373069 | Body mass and fat mass in refractory asthma: an observational 1 year follow-up study |
| Q46217512 | Breathing exercises for asthma: a randomised controlled trial. |
| Q38845598 | Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma |
| Q37343600 | Bronchial thermoplasty for the treatment of asthma |
| Q30409292 | Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma |
| Q57415851 | Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma |
| Q57415828 | Bronchoprotective role for endogenous prostaglandin E2 |
| Q100629551 | Budesonide-formoterol reliever therapy in intermittent versus mild persistent asthma |
| Q57415803 | COPD and Hepatitis C |
| Q93004604 | COPD exacerbation phenotypes: The next frontier |
| Q57415755 | COPD: an autoimmune disease? |
| Q57415788 | COPD: an inhaled corticosteroid-resistant, oral corticosteroid-responsive condition |
| Q33982443 | CRTH2 expression on T cells in asthma |
| Q40245160 | Chemokine concentrations and mast cell chemotactic activity in BAL fluid in patients with eosinophilic bronchitis and asthma, and in normal control subjects |
| Q57415814 | Chronic cough |
| Q43059043 | Chronic cough and gastro-oesophageal reflux. |
| Q57415796 | Chronic cough: a rational approach to investigation and management |
| Q47421529 | Chronic obstructive pulmonary disease in non-smokers |
| Q44773552 | Chronic tonsillar enlargement and cough: preliminary evidence of a novel and treatable cause of chronic cough |
| Q34933891 | Clinical applications of assessment of airway inflammation using induced sputum |
| Q34154400 | Clinical, radiologic, and induced sputum features of chronic obstructive pulmonary disease in nonsmokers: a descriptive study. |
| Q42084246 | Clinicians should be proactive in testing for asthma |
| Q37711387 | Cluster analysis and clinical asthma phenotypes. |
| Q42550247 | Comment on: "Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting β-Agonists". |
| Q35535986 | Comparison of airway immunopathology of eosinophilic bronchitis and asthma |
| Q46925786 | Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. |
| Q41235059 | Comparison of the effects of salbutamol and adrenaline on airway smooth muscle contractility in vitro and on bronchial reactivity in vivo |
| Q36498020 | Comparison of three inhaled non-steroidal anti-inflammatory drugs on the airway response to sodium metabisulphite and adenosine 5'-monophosphate challenge in asthma |
| Q46866127 | Complex airway disease: an approach to assessment and management |
| Q92187266 | Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma |
| Q51713924 | Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists. |
| Q45162902 | Cough and asthma |
| Q35583383 | Cough and asthma. |
| Q45261428 | Cough and glottic-stop reflex sensitivity in health and disease |
| Q44355386 | Cough frequency in health and disease |
| Q39735177 | Cough frequency, cough sensitivity and health status in patients with chronic cough. |
| Q42143155 | Cross refractoriness between sodium metabisulphite and exercise induced asthma. |
| Q38196605 | Current evidence and future research needs for FeNO measurement in respiratory diseases |
| Q42118581 | Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines |
| Q48204581 | Cytometric Gating Stringency Impacts Studies of Type 2 Innate Lymphoid Cells in Asthma. |
| Q91557107 | DP2 antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment |
| Q51535108 | Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma. |
| Q39758123 | Detection of cough signals in continuous audio recordings using hidden Markov models. |
| Q35096011 | Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ) |
| Q55094022 | Development of irreversible airflow obstruction in a patient with eosinophilic bronchitis without asthma |
| Q57415826 | Dietary antioxidant vitamin intake and lung function in the general population |
| Q57415833 | Dietary magnesium, lung function, wheezing, and airway hyper-reactivity in a random adult population sample |
| Q36575045 | Dietary sodium intake and the risk of airway hyperreactivity in a random adult population. |
| Q57415733 | Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma |
| Q56706375 | Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma |
| Q104577783 | Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function |
| Q43043318 | Duplicate publication |
| Q55094013 | Duplicate publication |
| Q38177376 | EAACI position statement on asthma exacerbations and severe asthma |
| Q44338661 | Effect of 443c81, an inhaled mu-opioid receptor agonist in asthma |
| Q57415843 | Effect of Inhaled Prostaglandin E2on Allergen-induced Asthma |
| Q57415823 | Effect of cessation of short-term therapy with ipratropium bromide on lung function and airway responsiveness |
| Q57415825 | Effect of diuretics on allergen-induced contractions of passively sensitized human bronchi in vitro |
| Q36099476 | Effect of five genetic variants associated with lung function on the risk of chronic obstructive lung disease, and their joint effects on lung function |
| Q41143678 | Effect of inhaled prostaglandin E2 on bronchial reactivity to sodium metabisulphite and methacholine in patients with asthma. |
| Q37582484 | Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. |
| Q57415832 | Effect of regular terbutaline and budesonide on bronchial reactivity to allergen challenge |
| Q35716134 | Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial |
| Q45855172 | Effectiveness of voriconazole in the treatment of Aspergillus fumigatus-associated asthma (EVITA3 study). |
| Q57415785 | Effects of montelukast compared to double dose budesonide on airway inflammation and asthma control |
| Q48745227 | Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. |
| Q46232572 | Eight o'clock ROCK! |
| Q28390947 | Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma |
| Q38892988 | Emerging Biologics in Severe Asthma |
| Q37711405 | Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma |
| Q50697152 | Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. |
| Q57415811 | Eosinophilic bronchitis - what is it and why is it important? |
| Q43517218 | Eosinophilic bronchitis is an important cause of chronic cough. |
| Q34087412 | Eosinophilic bronchitis: an important cause of prolonged cough. |
| Q35627726 | Eosinophilic bronchitis: clinical features, management and pathogenesis. |
| Q38169241 | Eosinophilic phenotypes of airway disease |
| Q57415756 | Eosinophils best marker of steroid response |
| Q57415801 | Eosinophils in Asthma and Airway Hyperresponsiveness |
| Q34255447 | Eosinophils in asthma and other allergic diseases. |
| Q46213282 | Erratum to: Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting β-Agonists |
| Q57415753 | Erratum: Extended extraocular phenotype of PROM1 mutation in kindreds with known autosomal dominant macular dystrophy |
| Q47281156 | Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma |
| Q38434820 | Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma |
| Q46947260 | Evidence of a role of tumor necrosis factor alpha in refractory asthma |
| Q113756592 | Exacerbation Profile and Risk Factors in a Type-2–Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes |
| Q26764891 | Exacerbations of COPD |
| Q93336161 | Exacerbations of severe asthma in patients treated with mepolizumab |
| Q38624065 | Exhaled Nitric Oxide For The Diagnosis Of Asthma In Adults And Children: A Systematic Review |
| Q57415729 | Exhaled nitric oxide and blood eosinophilia: Independent markers of preventable risk |
| Q51702712 | Exhaled nitric oxide and inhaled corticosteroid dose reduction in asthma: a cohort study. |
| Q37786111 | Exhaled nitric oxide in pulmonary diseases: a comprehensive review. |
| Q39025584 | Exhaled nitric oxide in the diagnosis of asthma in adults: a systematic review. |
| Q34381417 | Expression of CCR8 is increased in asthma |
| Q46879657 | Expression of CXCR6 and its ligand CXCL16 in the lung in health and disease |
| Q34514940 | Extended extraocular phenotype of PROM1 mutation in kindreds with known autosomal dominant macular dystrophy |
| Q57415836 | Factors influencing the occurrence of airway hyperreactivity in the general population: the importance of atopy and airway calibre |
| Q47720040 | Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. |
| Q37390146 | First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis |
| Q57415757 | Following Nero: fiddle while Rome burns, or is there a better way? |
| Q95810697 | Four-hour cough frequency monitoring in chronic cough |
| Q37340599 | FourFold Asthma Study (FAST): a study protocol for a randomised controlled trial evaluating the clinical cost-effectiveness of temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations. |
| Q28074582 | Fractional exhaled nitric oxide for the management of asthma in adults: a systematic review |
| Q62060634 | From the authors |
| Q89263428 | GLUCOLD, eosinophils and chronic obstructive pulmonary disease |
| Q24629653 | Genome-wide association study identifies five loci associated with lung function |
| Q57415713 | Glucocorticoids and Mepolizumab in Eosinophilic Asthma |
| Q40855500 | Glutamine supplementation in cystic fibrosis: A randomized placebo-controlled trial. |
| Q36597751 | Grand Rounds--City Hospital, Nottingham. A complicated case of community acquired pneumonia. |
| Q57415673 | Helicobacter pylori and lung function, asthma, atopy and allergic disease--A population-based cross-sectional study in adults |
| Q92526308 | ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma |
| Q57415709 | IL-33–Dependent Th2 Response after Rhinovirus Infection in Asthma: More Information Needed |
| Q55093999 | IL-4–expressing bronchoalveolar T cells from asthmatic and healthy subjects preferentially express CCR3 and CCR4 |
| Q57415791 | Idiopathic Chronic Cough and Organ-Specific Autoimmune Disease |
| Q48010545 | Idiopathic chronic cough and organ-specific autoimmune diseases: a case-control study. |
| Q35535595 | Idiopathic chronic cough: association with organ specific autoimmune disease and bronchoalveolar lymphocytosis. |
| Q34535033 | IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma. |
| Q55093939 | Improvement in health status following bronchopulmonary hygiene physical therapy in patients with bronchiectasis |
| Q48279227 | Improvement in health status following cough-suppression physiotherapy for patients with chronic cough |
| Q37711413 | Increased sputum and bronchial biopsy IL-13 expression in severe asthma |
| Q57415813 | Increases in eotaxin-positive cells in induced sputum from atopic asthmatic subjects after inhalational allergen challenge |
| Q57415807 | Induced Sputum Inflammatory Mediator Concentrations in Eosinophilic Bronchitis and Asthma |
| Q37711416 | Induced sputum and bronchial mucosal expression of interleukin-13 is not increased in chronic obstructive pulmonary disease. |
| Q44598199 | Induced sputum inflammatory mediator concentrations in chronic cough |
| Q51868746 | Inflammometry to assess airway diseases. |
| Q57415745 | Inflammometry: the current state of play |
| Q91053042 | Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology |
| Q51556449 | Inhaled corticosteroid dose-response on blood eosinophils in asthma - Authors' reply. |
| Q57415817 | Inhaled corticosteroids in COPD |
| Q36267937 | Inhaled frusemide and exercise induced asthma: evidence of a role for inhibitory prostanoids |
| Q42210687 | Integrated care pathways for airway diseases (AIRWAYS-ICPs). |
| Q35187262 | Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma |
| Q55094008 | Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma |
| Q38736845 | Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook |
| Q43058586 | Is the neutrophil the key effector cell in severe asthma? |
| Q36431204 | Isolation of filamentous fungi from sputum in asthma is associated with reduced post-bronchodilator FEV1. |
| Q43871835 | Journal policy on research funded by the tobacco industry |
| Q44805361 | Journal policy on research funded by the tobacco industry |
| Q53472819 | Journal policy on research funded by the tobacco industry |
| Q46243144 | Keeping 'a chest' of the literature |
| Q51445974 | Lessons from LAVOLTA. |
| Q57415810 | Letters to the Editor |
| Q43662388 | Leukotriene antagonists and symptom control in chronic persistent asthma |
| Q54986959 | Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. |
| Q42968905 | Location, location, location: microlocalisation of inflammatory cells and airway dysfunction |
| Q33818701 | Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial |
| Q42851015 | Long-term low-dose erythromycin in patients with unexplained chronic cough: a double-blind placebo controlled trial |
| Q47659308 | Look back with (some) anger, and a lot of pleasure |
| Q33674021 | Lung clearance index in adults with non-cystic fibrosis bronchiectasis. |
| Q46599014 | Lung function and blood levels of copper, selenium, vitamin C and vitamin E in the general population. |
| Q44396726 | Lung function decline and variable airway inflammatory pattern: longitudinal analysis of severe asthma. |
| Q38543189 | MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. |
| Q42870767 | Making the diagnosis of asthma. Measurement of airway responsiveness should be more readily available |
| Q35143482 | Management of asthma in adults: current therapy and future directions |
| Q34771784 | Management of chronic cough |
| Q51715332 | Mast-cell infiltration of airway smooth muscle in asthma. |
| Q26781270 | Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath |
| Q37711391 | Mepolizumab and exacerbations of refractory eosinophilic asthma |
| Q47776752 | Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease |
| Q47249808 | Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial |
| Q55093913 | Mepolizumab in refractory eosinophilic asthma |
| Q48065984 | Mepolizumab treatment in patients with severe eosinophilic asthma |
| Q34542340 | Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma |
| Q38509880 | Monitoring asthma in childhood: lung function, bronchial responsiveness and inflammation |
| Q38368506 | Monitoring asthma in children |
| Q51899833 | Monitoring of exhaled nitric oxide in primary care. |
| Q51545298 | Morbidity associated with oral corticosteroids in patients with severe asthma. |
| Q38116475 | Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? |
| Q36292293 | Multi-dimensional phenotyping: towards a new taxonomy for airway disease. |
| Q36481316 | Multiple inflammatory hits and the pathogenesis of severe airway disease |
| Q34767561 | New insights into the relationship between airway inflammation and asthma |
| Q35129653 | New insights into the role of the mast cell in asthma |
| Q45343649 | New year resolutions |
| Q42764623 | Non-eosinophilic asthma and the innate immune response |
| Q55094026 | Non-eosinophilic cor ticosteroid unresponsive asthma |
| Q36808167 | Noneosinophilic asthma: a distinct clinical and pathologic phenotype |
| Q36123192 | Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank |
| Q30698745 | Objective quantitative analysis of eosinophils and bronchial epithelial cells in induced sputum by laser scanning cytometry |
| Q46494889 | Observational study of the natural history of eosinophilic bronchitis |
| Q42087982 | Obstructive sleep apnoea: a cause of chronic cough. |
| Q43059927 | Occupational asthma due to low molecular weight agents: eosinophilic and non-eosinophilic variants |
| Q57415738 | Omalizumab: NICE to USE you, to LOSE you NICE |
| Q57415760 | On the shoulders of (real) giants |
| Q51699006 | Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. |
| Q50463875 | Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. |
| Q36169188 | Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. |
| Q35332978 | Peak expiratory flow sequence in acute exacerbations of asthma |
| Q43892994 | Peptic ulceration, Helicobacter pylori seropositivity and chronic obstructive pulmonary disease |
| Q40861599 | Pharmacokinetic optimisation of inhaled steroid therapy in asthma |
| Q38062584 | Phenotyping airways disease: an A to E approach. |
| Q47738767 | Precision medicine in airway diseases: moving to clinical practice |
| Q51549569 | Predictors of objective cough frequency in pulmonary sarcoidosis. |
| Q42549862 | Prednisolone response in patients with COPD. |
| Q57415818 | Prednisone-dependent asthma: inflammatory indices in induced sputum |
| Q43529443 | President elect kidnapped. Tsar very much |
| Q50643849 | Prevalence of inflammatory bowel disease in patients with airways disease. |
| Q34771772 | Prevalence, pathogenesis, and causes of chronic cough |
| Q34411970 | Primary human airway epithelial cell-dependent inhibition of human lung mast cell degranulation. |
| Q42701887 | Production of PGE2 by bovine cultured airway smooth muscle cells and its inhibition by cyclo-oxygenase inhibitors |
| Q57415829 | Production of PGE2 by bovine cultured airway smooth muscle cells: regulation by cAMP |
| Q33632072 | Qualitative analysis of high-resolution CT scans in severe asthma |
| Q34289144 | Quantitative analysis of high-resolution computed tomography scans in severe asthma subphenotypes. |
| Q37672008 | Quantitative computed tomography-derived clusters: redefining airway remodeling in asthmatic patients. |
| Q38125633 | Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma |
| Q35775998 | Recent insights into the relationship between airway inflammation and asthma. |
| Q28260345 | Recommendations for the management of cough in adults |
| Q57415839 | Refractoriness to inhaled sodium metabisulphite in subjects with mild asthma |
| Q57415830 | Regional Royal College of Physicians conference. Nottingham, September 1994 |
| Q58585951 | Remotely Monitored Therapy and Nitric Oxide Suppression Identifies Non-Adherence in Severe Asthma |
| Q92144166 | Reply to Boulet and Nair: Inhaled Corticosteroids and Adult Asthma |
| Q57415750 | Republished editorial: Following Nero: fiddle while Rome burns, or is there a better way? |
| Q26800021 | Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK) |
| Q62014524 | Respiratory effectiveness group study: Predictors of frequent severe asthma exacerbations |
| Q35535957 | Respiratory symptoms in patients with treated hypothyroidism and inflammatory bowel disease |
| Q48314227 | Response to Vestbo and Rodrigues-Roisin |
| Q112690343 | Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients |
| Q62060632 | S117 4 h cough frequency monitoring with the Leicester Cough Monitor |
| Q62060631 | S140 Predictors of 24-h cough frequency in acute cough |
| Q62060630 | S144 Acute cough: a longitudinal observational study |
| Q60312264 | S62 A Systematic Review of Factors Associated with Future Asthma Attacks to Inform a Risk Assessment Questionnaire |
| Q46977245 | Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma |
| Q38443013 | Safety of bronchial thermoplasty in patients with severe refractory asthma |
| Q34693644 | Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma |
| Q26740215 | Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) |
| Q39768068 | Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies |
| Q47905286 | Severe eosinophilic asthma: a roadmap to consensus |
| Q57415747 | Single inhaler maintenance and reliever therapy (SMART) in general practice asthma management: where are we? |
| Q57415809 | Sputum Cysteinyl Leukotrienes Increase 24 Hours after Allergen Inhalation in Atopic Asthmatics |
| Q37369908 | Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD |
| Q47897731 | Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. |
| Q55094017 | Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial |
| Q35537515 | Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. |
| Q45306299 | Sputum eosinophilia in idiopathic pulmonary fibrosis. |
| Q43043424 | Sputum induction to assess airway inflammation: is it an inflammatory stimulus? |
| Q50497911 | Stability of inflammatory phenotypes in asthma. |
| Q38960423 | Step 4: stick or twist? A review of asthma therapy |
| Q57415852 | Steroid responsive cardiomyopathy |
| Q34211965 | Systemic and pulmonary inflammation is independent of skeletal muscle changes in patients with chronic obstructive pulmonary disease. |
| Q36573494 | Systemic effects of salbutamol and salmeterol in patients with asthma |
| Q43060391 | TB guidelines |
| Q51695315 | TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. |
| Q36809486 | TNF-alpha in asthma |
| Q43111808 | Temporal assessment of airway remodeling in severe asthma using quantitative computed tomography. |
| Q55093915 | The A to E of airway disease |
| Q27025354 | The Asthma Control Questionnaire as a clinical trial endpoint: past experience and recommendations for future use |
| Q45155071 | The BREATHE study: Breathing REtraining for Asthma--Trial of Home Exercises. a protocol summary of a randomised controlled trial. |
| Q57415780 | The Leicester Cough Monitor: preliminary validation of an automated cough detection system in chronic cough |
| Q57415805 | The Relation Between Peripheral Blood Leukocyte Counts and Respiratory Symptoms, Atopy, Lung Function, and Airway Responsiveness in Adults |
| Q61890874 | The Risk Factors That Identify With Airflow Obstruction And Exacerbations In Severe Asthma |
| Q61890875 | The Role Of A Peripheral Blood Eosinophil Count As A Biomarker For A Sputum Eosinophilia In COPD Exacerbations |
| Q112648238 | The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D2 Production Are Attenuated by PGD2 Receptor 2 Antagonism |
| Q46933881 | The Significance of Eosinophilic Inflammation in COPD. |
| Q93073752 | The Use of Inhaled Corticosteroids to Prevent Acute Exacerbations of COPD: A Pro/Con Debate |
| Q35203676 | The assessment of quality of life in acute cough with the Leicester Cough Questionnaire (LCQ-acute). |
| Q51638821 | The asthmas in 2015 and beyond: a Lancet Commission. |
| Q98503610 | The burden of exacerbations in mild asthma: a systematic review |
| Q38764451 | The current and future role of biomarkers in type 2 cytokine-mediated asthma management |
| Q61890820 | The detection of free-living H. influenzae in the airways of patients with COPD |
| Q41106553 | The effect of amiloride on the airway response to metabisulphite in asthma: a negative report |
| Q57415824 | The effect of inhaled heparin on bronchial reactivity to sodium metabisulphite and methacholine in patients with asthma |
| Q33697776 | The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β2-agonists in the United Kingdom: a cross-sectional analysis |
| Q47880674 | The influence of age on induced sputum differential cell counts in normal subjects |
| Q57415736 | The long term outcome of patients with unexplained chronic cough |
| Q47996845 | The relationship between clinical outcomes and medication adherence in difficult-to-control asthma |
| Q35201868 | The role of CT scanning in multidimensional phenotyping of COPD. |
| Q39116335 | The role of biomarkers in the management of airways disease |
| Q55094029 | The safety and success rate of sputum induction using a low output ultrasonic nebuliser |
| Q47727199 | The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. |
| Q37261439 | The use of exhaled nitric oxide in the management of asthma. |
| Q34627601 | The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial |
| Q34933928 | The use of induced sputum in clinical trials |
| Q43043644 | The use of induced sputum to investigate airway inflammation |
| Q38608928 | Theobromine for the treatment of persistent cough: a randomised, multicentre, double-blind, placebo-controlled clinical trial |
| Q44393665 | Thorax: the Cappuccino years |
| Q57415724 | Thorax: the prostate years |
| Q57415749 | Thorax: the teenage years |
| Q47330145 | Transcutaneous monitoring of blood gases: is it comparable with arterialized earlobe sampling? |
| Q40940115 | Treatable traits: toward precision medicine of chronic airway diseases |
| Q37004568 | Tumor necrosis factor-alpha: a promising therapeutic target for asthma? |
| Q51631534 | Two Lovely Black Eyes; Oh, what a surprise! |
| Q125464318 | Type 2 inflammation and biological therapies in asthma: Targeted medicine taking flight |
| Q46568175 | Use of long-acting beta2 agonists in arginine-16 homozygous patients with asthma |
| Q47645175 | Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design |
| Q55093966 | Vascular remodeling is a feature of asthma and nonasthmatic eosinophilic bronchitis |
| Q51447442 | What can we learn from blood granulocyte patterns in patients with asthma? |
| Q38339755 | What goes up must come down: biomarkers and novel biologicals in severe asthma. |
| Q52265451 | Will I get addicted to my asthma treatment? |
| Q57415774 | Will exhaled nitric oxide monitoring become routine in managing asthma? |
| Q57415719 | Year in review 2013: paediatric and adult clinical studies |
| Q38376166 | Year in review 2014. Paediatric and adult clinical studies |
Search more.